8-K: NeOnc Technologies Names Amir Heshmatpour CEO, Chen Shifts to CSO

NeOnc Technologies Holdings, Inc. announced the appointment of Amir Heshmatpour as its new CEO, with founder Dr. Thomas Chen transitioning to Chief Medical and Scientific Officer.

Summary

• Amir Heshmatpour has been appointed Chief Executive Officer of NeOnc Technologies Holdings, Inc., effective October 31, 2025, and will also continue as President and Executive Chairman.
• Dr. Thomas Chen resigned as CEO, effective October 31, 2025, and will now serve as Chief Medical Officer and Chief Scientific Officer, while remaining Vice Chairman of the Board.
• Mr. Heshmatpour will receive a nominal salary of $1 per year until a formal employment agreement is finalized and was granted 1,200,000 shares of restricted stock, vesting in two tranches starting January 2, 2026.
• The company detailed significant related party transactions involving Mr. Heshmatpour and entities he controls, including advisory fees of $500,000 in 2023 and a $2,500,000 payment post-direct listing to AFH Holdings and Advisory, LLC.
• A bridge loan from HCWG LLC (partially owned by Mr. Heshmatpour, Dr. Chen, and CFO Keithly Garnett) totaling $11,748,464 was converted into 979,039 shares of common stock at $12 per share on June 14, 2024, resulting in a $2,069,923 loss on extinguishment.
• Mr. Heshmatpour advanced approximately $300,000 to the company in February 2025, with a 50% original issue discount, entitling him to $600,000 upon repayment, which occurred after the direct listing.
• A Line of Credit Agreement for up to $10.0 million was established with HCWG LLC on October 11, 2024, bearing 10.0% interest, and included a warrant issuance leading to 164,500 shares issued to HCWG in April 2025.
• NeOnc is a multi-Phase 2 clinical-stage biopharmaceutical company focused on CNS cancers, with its NEO platform protected by over 179 worldwide patents.

Sentiment

Score: 6

Explanation: The appointment of a new CEO with a strong financial background and the founder's shift to a dedicated scientific role are positive developments that could drive future growth and clinical progress. The mention of a $50 million partnership and global expansion are also favorable. However, the detailed related-party transactions, including high-cost loans and significant payments to entities associated with management, introduce concerns about corporate governance and the company's ability to secure arm's-length financing, tempering overall sentiment.

Positives

• Appointment of Amir Heshmatpour as CEO, who has a strong background in corporate strategy, capital formation, and business development, including leading IPO transactions totaling over $1.5 billion.
• Dr. Thomas Chen, the company's founder, will now focus exclusively on his roles as Chief Medical Officer and Chief Scientific Officer, potentially accelerating clinical trials and scientific development.
• Recent achievements under Mr. Heshmatpour's presidency include a $50 million strategic partnership with Quazar Investment and the establishment of a UAE-based subsidiary, NuroMENA, with high-profile leadership.
• Expansion of the Scientific Advisory Board with world-renowned neuro-oncologists.
• The company's NEO platform has over 179 worldwide patents and is pioneering intranasal delivery for brain cancer and CNS diseases.
• NEO100 and NEO212 therapeutics are in Phase II human clinical trials and have FDA Fast-Track and Investigational New Drug (IND) status.

Negatives

• Significant related party transactions, including substantial advisory fees and loan arrangements with entities controlled by or affiliated with current management and directors, which could raise corporate governance concerns.
• The bridge loan from HCWG LLC carried a 50% Original Issue Discount (OID), indicating a high cost of capital from related parties.
• The conversion of the bridge loan resulted in a $2,069,923 loss on extinguishment for the company.
• Mr. Heshmatpour's initial CEO compensation is $1 per year, but he received a substantial restricted stock grant (1,200,000 shares) and has been involved in multiple lucrative related-party transactions.
• The company's reliance on related-party financing (Bridge Loan, Line of Credit, Executive Chairman advances) suggests challenges in securing external, arm's-length financing.

Risks

• Forward-looking statements caution about the 'failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds,' indicating uncertainty around a key strategic partnership.
• Reliance on related-party financing and advisory services could lead to conflicts of interest and potentially unfavorable terms for the company compared to arm's-length transactions.
• The high Original Issue Discount (50%) on the bridge loan and the 10-14% interest rate on the line of credit indicate a high cost of capital, which could strain financial resources.
• The company operates in the biopharmaceutical sector, which inherently involves significant clinical development risks, regulatory hurdles, and uncertainties regarding commercialization.
• The vesting schedule for Mr. Heshmatpour's restricted stock is tied to continued employment, but the initial $1 salary until a formal agreement is finalized could create uncertainty regarding long-term executive commitment or future compensation demands.

Future Outlook

The company aims to advance its lead candidates toward commercialization, accelerate clinical trials, and drive scientific development, leveraging its NEO platform and patent portfolio to transform care for patients with brain cancer and CNS diseases. There is an ongoing strategic partnership with Quazar Investment for $50 million, though its finalization is subject to certain risks.

Management Comments

• "It has been the honor of a lifetime to found NeOnc and lead it to this pivotal stage, and I have the utmost confidence that Amir is the ideal leader to steer the company into its future." Dr. Thomas Chen
• "His proven expertise in corporate strategy, capital formation, and global business development is precisely what NeOnc needs as we advance our lead candidates toward commercialization." Dr. Thomas Chen
• "This transition allows me to dedicate my full attention to what I am most passionate about: accelerating our clinical trials and driving the science that has the potential to transform outcomes for patients with brain cancer." Dr. Thomas Chen
• "It is an extraordinary honor to lead NeOnc Technologies into its next phase of growth." Amir F. Heshmatpour
• "With Dr. Chen now dedicating his full focus to accelerating patient enrollment and advancing our clinical trials, we are unlocking the full potential of our NEO platform, a scientific engine protected by more than 179 worldwide patents and pioneering the first-mover advantage in intranasal delivery for brain cancer and central nervous system diseases." Amir F. Heshmatpour
• "Together, we are not just developing therapies, we are transforming the future of care for patients who have been told there are no options left. This is NeOncs moment to change the standard of care and to give hope back to those who need it most." Amir F. Heshmatpour

Industry Context

This management restructuring positions NeOnc Technologies, a clinical-stage biopharmaceutical company, to potentially accelerate its drug development in the competitive CNS cancer therapeutics market. The focus on intranasal delivery for brain cancer represents an innovative approach within the industry, aiming to overcome the blood-brain barrier challenge. The strategic partnership with Quazar Investment and the establishment of a UAE subsidiary suggest efforts to expand global reach and secure funding, common strategies for biotech firms advancing through clinical phases.

Comparison to Industry Standards

• The company's NEO platform, with over 179 worldwide patents, suggests a strong intellectual property position, which is a key competitive advantage in the biopharmaceutical industry.
• Having two therapeutics (NEO100 and NEO212) in Phase II human clinical trials with FDA Fast-Track and IND status indicates significant progress, aligning with typical development timelines for innovative biotech companies.
• The $50 million strategic partnership with Quazar Investment is a substantial capital infusion, comparable to significant funding rounds seen in other clinical-stage biotech firms, though the risks around its finalization are notable.
• The establishment of NuroMENA as a UAE-based subsidiary with high-profile leadership reflects a strategy for market expansion and regional funding, similar to global expansion efforts by other biopharmaceutical companies seeking to diversify their investor base and clinical trial sites.
• The high cost of capital from related-party loans (50% OID, 10-14% interest) is significantly above typical commercial lending rates for established companies, suggesting a higher risk profile or limited access to conventional financing, which is not uncommon for early-stage biotechs but warrants scrutiny.

Management Changes

Corporate Governance

Related Party Transactions

• Engagement agreement with AFH Holdings and Advisory, LLC (controlled by Mr. Heshmatpour) for public listing assistance, earning $500,000 in 2023 and a $2,500,000 payment post-direct listing, plus a $500,000 amendment fee.
• Share Exchange Agreement (April 7, 2023) resulted in Mr. Heshmatpour, AFH, and affiliates owning 34.4% of the fully diluted shares.
• Bridge Loan from HCWG LLC (partially owned by Mr. Heshmatpour, Dr. Chen, and CFO Keithly Garnett) with a 50% Original Issue Discount, totaling $11,748,464, converted to common stock.
• Advances of approximately $300,000 from Mr. Heshmatpour in February 2025, with a 50% OID, repaid as $600,000.
• Line of Credit Agreement for up to $10.0 million with HCWG LLC, bearing 10.0% interest and including a warrant issuance that led to 164,500 shares issued to HCWG.
• Stock-based compensation: Mr. Heshmatpour received 1,000,000 restricted shares in January 2024 and 200,000 restricted shares in October 2024, both vesting on October 25, 2025.
• In connection with his CEO appointment, Mr. Heshmatpour was granted an additional 1,200,000 shares of restricted stock on November 6, 2025, with vesting commencing January 2, 2026.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through new CEO's strategic leadership and accelerated clinical development. Dilution from conversion of related-party debt to equity and new restricted stock grants. Concerns regarding the extent and terms of related-party transactions and their impact on company valuation and governance.
• Employees: Dr. Chen's transition allows him to focus on scientific leadership, potentially benefiting R&D teams. New CEO brings a focus on corporate growth and commercialization.
• Customers (future patients): Accelerated clinical trials and scientific focus could lead to new therapies for CNS cancers, offering hope for patients with limited options.
• Creditors: HCWG LLC, as a significant creditor and related party, has seen its debt converted to equity and holds a line of credit, indicating a close financial relationship with the company.

Next Steps

• Finalize a formal employment agreement for Amir Heshmatpour.
• Advance lead candidates (NEO100 and NEO212) toward commercialization.
• Accelerate patient enrollment and clinical trials.
• Finalize the $50 million strategic partnership with Quazar Investment.
• Continue to drive scientific development of the NEO platform.

Key Dates

Recommendation

The appointment of a new CEO with a strong track record in capital markets and the strategic shift of the founder to a dedicated scientific role are positive developments that could drive future growth and clinical progress. The company's strong patent portfolio and Phase II assets are also encouraging. However, the extensive and high-cost related-party transactions, including significant OID on loans and substantial payments to affiliated entities, raise concerns about corporate governance, potential conflicts of interest, and the company's ability to secure financing on arm's-length terms. These factors introduce a level of risk and uncertainty that warrants a "hold" recommendation, suggesting investors monitor how the new leadership addresses these governance issues and progresses with its strategic initiatives and clinical pipeline.

Keywords

NeOnc Technologies, NTHI, CEO appointment, Amir Heshmatpour, Thomas Chen, Chief Medical Officer, Chief Scientific Officer, biopharmaceutical, CNS cancers, brain cancer, Phase II clinical trials, FDA Fast-Track, IND status, restricted stock, related party transactions, corporate governance, AFH Holdings, HCWG LLC, bridge loan, line of credit, equity incentive plan, Quazar Investment, NuroMENA, NASDAQ